Frazier Life Sciences Management L.P. Has $11.31 Million Stock Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Frazier Life Sciences Management L.P. raised its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 22.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 583,327 shares of the company's stock after buying an additional 106,000 shares during the quarter. Frazier Life Sciences Management L.P. owned about 1.67% of Oruka Therapeutics worth $11,311,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock valued at $31,231,000 after purchasing an additional 1,572,853 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Oruka Therapeutics by 2,348.6% in the fourth quarter. Geode Capital Management LLC now owns 342,418 shares of the company's stock valued at $6,643,000 after buying an additional 328,434 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in Oruka Therapeutics during the 4th quarter worth about $54,000. Wellington Management Group LLP raised its holdings in Oruka Therapeutics by 15.8% during the 4th quarter. Wellington Management Group LLP now owns 95,089 shares of the company's stock worth $1,844,000 after purchasing an additional 12,952 shares during the last quarter. Finally, Barclays PLC bought a new stake in Oruka Therapeutics during the 4th quarter worth about $1,446,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ORKA has been the subject of several recent research reports. Wall Street Zen raised Oruka Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday. Wolfe Research began coverage on Oruka Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Friday, February 7th. BTIG Research started coverage on Oruka Therapeutics in a research report on Thursday. They set a "buy" rating for the company. Finally, Wedbush reiterated an "outperform" rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, May 15th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Oruka Therapeutics presently has an average rating of "Buy" and a consensus price target of $40.38.

Oruka Therapeutics Trading Down 2.1%

ORKA stock traded down $0.24 during trading hours on Friday, hitting $10.95. 135,502 shares of the stock were exchanged, compared to its average volume of 225,915. The firm has a market capitalization of $409.98 million, a P/E ratio of -1.75 and a beta of 0.25. The company has a 50-day simple moving average of $9.79 and a two-hundred day simple moving average of $14.20. Oruka Therapeutics, Inc. has a 12 month low of $5.49 and a 12 month high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.17. On average, equities research analysts predict that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.